- Home
- TXG
as of 03-18-2026 3:41pm EST
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | PLEASANTON |
| Market Cap: | 2.8B | IPO Year: | 2019 |
| Target Price: | $17.18 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Hold | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | 76.97 |
| 52 Week Low/High: | $6.78 - $23.56 | Next Earning Date: | 05-07-2026 |
| Revenue: | $245,893,000 | Revenue Growth: | 68.06% |
| Revenue Growth (this year): | -3.65% | Revenue Growth (next year): | 7.26% |
| P/E Ratio: | -49.31 | Index: | N/A |
| Free Cash Flow: | 130.1M | FCF Growth: | N/A |
AI-Powered TXG Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of 10x Genomics Inc. (TXG)
Chief Executive Officer
Avg Cost/Share
$22.92
Shares
16,152
Total Value
$367,096.61
Owned After
1,205,527
Director
Avg Cost/Share
$19.41
Shares
7,579
Total Value
$147,108.39
Owned After
26,780
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$18.58
Shares
9,632
Total Value
$178,927.88
Owned After
1,205,527
SEC Form 4
See Remarks
Avg Cost/Share
$18.58
Shares
7,826
Total Value
$145,378.91
Owned After
424,779
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$18.58
Shares
8,968
Total Value
$166,593.16
Owned After
288,417
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Saxonov Serge | TXG | Chief Executive Officer | Mar 2, 2026 | Sell | $22.92 | 16,152 | $367,096.61 | 1,205,527 | |
| Teichmann Sarah A. | TXG | Director | Feb 25, 2026 | Sell | $19.41 | 7,579 | $147,108.39 | 26,780 | |
| Saxonov Serge | TXG | Chief Executive Officer | Feb 23, 2026 | Sell | $18.58 | 9,632 | $178,927.88 | 1,205,527 | |
| Hindson Benjamin J. | TXG | See Remarks | Feb 23, 2026 | Sell | $18.58 | 7,826 | $145,378.91 | 424,779 | |
| Taich Adam | TXG | Chief Financial Officer | Feb 23, 2026 | Sell | $18.58 | 8,968 | $166,593.16 | 288,417 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 12, 2026 · 100% conf.
1D
-3.08%
$16.97
Act: +3.48%
5D
-7.24%
$16.24
Act: +7.82%
20D
-7.20%
$16.25
txg-20260212false000177078700017707872026-02-122026-02-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026
10x Genomics, Inc. (Exact name of registrant as specified in its charter)
Delaware 001-39035 45-5614458
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
6230 Stoneridge Mall Road Pleasanton, California 94588 (925) 401-7300 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 12, 2026, 10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit No. Description of Exhibits
99.1Press Release dated February 12, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
10x Genomics, Inc.
By: /s/ Randy Wu Name: Randy Wu
Title: General Counsel and Secretary
Date:February 12, 2026
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
1D
-3.08%
$16.97
Act: +3.48%
5D
-7.24%
$16.24
Act: +7.82%
20D
-7.20%
$16.25
txg-20260111false000177078700017707872026-01-112026-01-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2026
10x Genomics, Inc. (Exact name of registrant as specified in its charter)
Delaware 001-39035 45-5614458
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
6230 Stoneridge Mall Road Pleasanton, California 94588 (925) 401-7300 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On January 11, 2026, 10x Genomics, Inc. issued a press release announcing preliminary, unaudited select financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing..
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit No. Description of Exhibits
99.1Press Release dated January 11, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
10x Genomics, Inc.
By: /s/ Randy Wu Name: Randy Wu
Title: General Counsel and Secretary
Date: January 12, 2026
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
Q3 2025 Earnings
8-KNov 6, 2025
txg-20251106false000177078700017707872025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025
10x Genomics, Inc. (Exact name of registrant as specified in its charter)
Delaware 001-39035 45-5614458
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
6230 Stoneridge Mall Road Pleasanton, California 94588 (925) 401-7300 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol Name of each exchange on which registered
Class A common stock, par value $0.00001 per share TXG The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, 10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits.
Exhibit No. Description of Exhibits
99.1Press Release dated November 6, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
10x Genomics, Inc.
By: /s/ Eric S. Whitaker
Name: Eric S. Whitaker
Title: Chief Legal Officer
Date: November 6, 2025
Compare TXG vs Leading Stocks
See how TXG stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TXG 10x Genomics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.